These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Loria V; Dato I; Graziani F; Biasucci LM Mediators Inflamm; 2008; 2008():135625. PubMed ID: 18382609 [TBL] [Abstract][Full Text] [Related]
43. PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis. Zheng W; Warner R; Ruggeri R; Su C; Cortes C; Skoura A; Ward J; Ahn K; Kalgutkar A; Sun D; Maurer TS; Bonin PD; Okerberg C; Bobrowski W; Kawabe T; Zhang Y; Coskran T; Bell S; Kapoor B; Johnson K; Buckbinder L J Pharmacol Exp Ther; 2015 May; 353(2):288-98. PubMed ID: 25698787 [TBL] [Abstract][Full Text] [Related]
44. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. Askari AT; Brennan ML; Zhou X; Drinko J; Morehead A; Thomas JD; Topol EJ; Hazen SL; Penn MS J Exp Med; 2003 Mar; 197(5):615-24. PubMed ID: 12615902 [TBL] [Abstract][Full Text] [Related]
45. The potentiation of myeloperoxidase activity by the glycosaminoglycan-dependent binding of myeloperoxidase to proteins of the extracellular matrix. Kubala L; Kolářová H; Víteček J; Kremserová S; Klinke A; Lau D; Chapman AL; Baldus S; Eiserich JP Biochim Biophys Acta; 2013 Oct; 1830(10):4524-36. PubMed ID: 23707661 [TBL] [Abstract][Full Text] [Related]
49. Gamma-glutamyl transferase and cardiovascular disease. Ndrepepa G; Kastrati A Ann Transl Med; 2016 Dec; 4(24):481. PubMed ID: 28149843 [TBL] [Abstract][Full Text] [Related]
50. Decreased nucleotide excision repair in steatotic livers associates with myeloperoxidase-immunoreactivity. Schults MA; Nagle PW; Rensen SS; Godschalk RW; Munnia A; Peluso M; Claessen SM; Greve JW; Driessen A; Verdam FJ; Buurman WA; van Schooten FJ; Chiu RK Mutat Res; 2012 Aug; 736(1-2):75-81. PubMed ID: 22100520 [TBL] [Abstract][Full Text] [Related]
51. Myeloperoxidase and coronary arterial disease: from research to clinical practice. Roman RM; Wendland AE; Polanczyk CA Arq Bras Cardiol; 2008 Jul; 91(1):e11-9. PubMed ID: 18660935 [TBL] [Abstract][Full Text] [Related]
55. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Maes M; Ruckoanich P; Chang YS; Mahanonda N; Berk M Prog Neuropsychopharmacol Biol Psychiatry; 2011 Apr; 35(3):769-83. PubMed ID: 20561554 [TBL] [Abstract][Full Text] [Related]
56. Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease. Churg A; Marshall CV; Sin DD; Bolton S; Zhou S; Thain K; Cadogan EB; Maltby J; Soars MG; Mallinder PR; Wright JL Am J Respir Crit Care Med; 2012 Jan; 185(1):34-43. PubMed ID: 21997333 [TBL] [Abstract][Full Text] [Related]
57. Myeloperoxidase: A new player in autoimmunity. Strzepa A; Pritchard KA; Dittel BN Cell Immunol; 2017 Jul; 317():1-8. PubMed ID: 28511921 [TBL] [Abstract][Full Text] [Related]
58. Myeloperoxidase and its contributory role in inflammatory vascular disease. Lau D; Baldus S Pharmacol Ther; 2006 Jul; 111(1):16-26. PubMed ID: 16476484 [TBL] [Abstract][Full Text] [Related]
59. The Roles of Neutrophil-Derived Myeloperoxidase (MPO) in Diseases: The New Progress. Lin W; Chen H; Chen X; Guo C Antioxidants (Basel); 2024 Jan; 13(1):. PubMed ID: 38275657 [TBL] [Abstract][Full Text] [Related]